Is Rybelsus Semaglutide the Same as Ozempic?

Same molecule, entirely different products: what the MHRA has authorised

The active ingredient in Rybelsus, Ozempic and Wegovy is semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone involved in appetite signalling and blood-sugar regulation. But the MHRA issues a separate marketing authorisation to each branded medicine, specifying exactly which patients it may be prescribed for, at which doses, and via which route. Sharing a molecule does not make these products interchangeable in law or in clinical practice.

Ozempic (Novo Nordisk) is a once-weekly subcutaneous injection licensed for type 2 diabetes in the UK, at doses of 0.25 mg, 0.5 mg, 1 mg and 2 mg. Rybelsus (also Novo Nordisk) is a once-daily tablet licensed for type 2 diabetes in the UK, at 3 mg, 7 mg and 14 mg, strengths specific to the diabetes indication and its absorption profile. The NHS semaglutide medicines page is clear that neither of these brands is licensed for weight management. Using either for weight loss would be off-label prescribing, which carries additional clinical and regulatory considerations that a prescriber must weigh up individually.

This is not a technicality. Licensing reflects the clinical evidence submitted to the regulator for that specific product, dose range and patient population. The diabetes doses of Rybelsus, for instance, were studied in trials designed around glycaemic outcomes, not weight loss endpoints.

Why Rybelsus tablets are not the same as the new Wegovy weight-loss tablets

Since June 2026, there is a second oral semaglutide product in the UK: Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed here for weight management. It is easy to assume this is just Rybelsus by another name. It is not.

The Wegovy tablet schedule runs 1.5 mg, 4 mg, 9 mg, up to a 25 mg maintenance dose, strengths that bear no relation to the Rybelsus 3 mg, 7 mg and 14 mg steps. The two products were studied in different trials, in different patient populations, for different outcomes. If you look into the Rybelsus 7 mg tablet expecting weight-loss dosing, you will find the diabetes regimen, not the weight-management one. For a fuller comparison of how the oral options are structured, our page on semaglutide tablets sets out the distinctions clearly.

The Wegovy tablet's absorption mechanism also uses a co-formulation with the absorption enhancer SNAC, taken first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before food or other medicines. The clinical profile, the licensed population (adults with BMI of 30 or above, or 27 to 29.9 with a weight-related condition) and the supporting trial evidence are specific to this product. Treating it as equivalent to Rybelsus would be a clinical error.

What IS licensed in the UK if weight management is the goal

Two semaglutide products carry UK weight-management licences: Wegovy injection and, from summer 2026, Wegovy tablets. The injection has been licensed since 2023, with the MHRA adding a higher 7.2 mg maintenance dose in early 2026. In the STEP 1 trial (published in the New England Journal of Medicine) participants using the 2.4 mg weekly injection saw an average body-weight reduction of around 15% over 68 weeks. The Wegovy tablet, studied in the OASIS 4 trial, showed an average reduction of around 13.6% over 64 weeks regardless of adherence, rising to roughly 17% among participants who stayed fully adherent to treatment.

The other licensed option is tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist from Eli Lilly, which the NICE appraisal TA1026 assessed and recommended for adults with a BMI of 35 or above alongside at least one weight-related condition. SURMOUNT-5, a head-to-head trial against semaglutide 2.4 mg, found tirzepatide produced greater average weight reduction. Both remain prescription-only medicines, requiring clinical assessment before a prescriber can issue a prescription.

You can explore the full picture of what these treatments involve on our weight-loss treatment overview, or read specifically about the Wegovy tablet if the oral route interests you. If you are weighing up the costs and what a private prescription includes, our treatment page sets out what is covered transparently.

The practical question: can a prescriber switch you between these products?

A prescriber can, in principle, make off-label use of a medicine where clinical evidence supports it and the patient's circumstances justify it. But that is a decision made during a proper clinical assessment, with documented reasoning, not a workaround for a product being out of stock or cheaper. Reports of people seeking Ozempic or Rybelsus specifically for weight loss, rather than going through the licensed weight-management pathway, prompted the MHRA's Yellow Card reporting system to receive a growing number of submissions about adverse effects from patients using these products outside their licensed indications.

If your question is really about which semaglutide-based treatment might be suitable for you, the honest answer is that it depends on your health history, your BMI, and what a prescriber concludes after a proper consultation. For a broader look at how oral and injectable options compare, our page on whether semaglutide tablets are the same as Ozempic addresses that angle directly. And if you want to understand the Rybelsus side of this in more depth, the relationship between Rybelsus and semaglutide more broadly is covered there.

At nume, our prescribers review each consultation personally before anything is approved. If weight management is your aim, the appropriate route is through the licensed pathway, and our team can assess whether Wegovy or Mounjaro is likely to suit your situation. Speak to our prescribers to get started, or if you would like more background on how the injection fits into the wider picture, our page on Ozempic and semaglutide tablets covers that context in detail.